

Research Ethics Committee Reference Number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time
12/LO/0062	Phase 3 Randomized Double-Blind Placebo-Controlled Study of Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization	20	01/11/2013	Closed - Follow Up Complete	N
11/SC/0524	Phase 3b Randomized Open Label Study to Evaluate Switching from Regimens Consisting of a NNRTI plus Emtricitabine (FTC) and TDF to EVG/COBI/FTC/TDF in Virologically Suppressed, HIV1 Infected Patients	5	31/12/2012	Closed - Follow Up Complete	Y
12/SC/0035	A 6-month safety and benefit study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of 6,200 paediatric subjects 4-11 years old with persistent asthma	2	31/08/2015	Closed - In Follow Up	Y
12/SC/0098	A safety and efficacy study of inhaled fluticasone propionate/ salmeterol combination versus inhaled fluticasone propionate in the treatment of adolescent & adult subjects with persistent asthma	2	30/06/2016	Closed - In Follow Up	N
11/SC/0523	Phase 3b Randomized Open Label Study to Evaluate Switching from Regimens Consisting of a PI/r + FTC/TDF to EVG/COBI/FTC/TDF in Virologically Suppressed HIV 1 Infected Pts (GS 0115)	5	14/12/2012	Closed - Follow Up Complete	N
12/EE/0176	Randomised Ph 4 placebo-controlled comparative study to evaluate efficacy/safety of tapering MTX dosage vs maintaining dosage in severe active RA patients showing inadequate response to prior conventional DMARDs treatment & initiated RoActemra? in combination with MTX	5	01/04/2014	Closed - In Follow Up	Y
11/WM/0050	A PHASE 3, MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF EPRATUZUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS SUBJECTS	1	01/05/2013	Closed - Follow Up Complete	Y
11/LO/1921	Randomized 2 arm open-label multicenter Phase 2 trial assessing efficacy & safety of pertuzumab given in combination with trastuzumab & aromatase inhibitor in 1st line patients with HER2+ & hormone receptor+ advanced (metastatic/locally advanced) breast cancer	5	29/01/2016	Closed - In Follow Up	N
12/EM/0389	Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis	6	01/06/2013	Closed - In Follow Up	Y
11/AL/0167	CLINICAL INVESTIGATION OF A DES (MISTENT? SYSTEM) WITH SIROLIMUS AND A BIOABSORBABLE POLYMER FOR THE TREATMENT OF PATIENTS WITH DE NOVO LESIONS IN NATIVE CORONARY ARTERIES	8	21/07/2011	Closed - Follow Up Complete	N

10/H0808/137	GORE HELEX Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent stroke or Imaging-confirmed TIA in patients with Patent Foramen Ovale (PFO)	20	04/12/2017	Open	N/A
12/NI/0181	REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus? Valve System ? Evaluation of Safety and Performance.	6	31/01/2014	Closed - in follow up	Y
11/SC/0329	Phase 3 Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study to Evaluate Safety/Efficacy of Ustekinumab Maintenance Therapy in Subjects w/ Mod/Severe Active Crohn?s Disease Who Failed/Are Intolerant to TNF Antagonist Therapy	1	01/10/2017	Closed - In Follow Up	Y
11/LO/1498	PROTEase inhibitor (DRV/rtv) in mono- or triple therapy in suppressed HIV-1 infected subjects.	10	31/01/2013	Closed - In Follow Up	Y
11/SC/0243	Safety/Efficacy of 240 mg BI 201335 once daily in combo + pegylated interferon alpha 2a & ribavirin for treatment of chronic HCV genotype 1 infection in HIV/HCV-co-infected patients (BI HEPC)	3	01/08/2015	Withdrawn	N
11/LO/0751	A Phase 3, Open-label Safety study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment	5	01/11/2013	Closed - Follow Up Complete	Y
13/LO/0006	A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects (PHOTON 2)	6	30/06/2013	Closed - Follow Up Complete	N
12/NW/0105	Phase III Randomized Double-Blind Placebo-Controlled Adaptive Design Study of Efficacy/Safety/Tolerability of Single Infusion of MK-3415 , MK-6072, and MK-3415A in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection	1	14/02/2014	Closed - In follow up	Y
10/H1102/85	Protocol H8A-MC-LZAO Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid ? Antibody in Patients with Alzheimer?s Disease	N/A	N/A	Closed - In Follow Up	N/A
11/LO/0537	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis	6	27/02/2015	Closed - In Follow Up	Y
12/NW/0723	A multi-centre, open-label, long term safety extension of phase II studies ABE4869g and ABE4955g in patients with mild to moderate Alzheimer's Disease.	4	N/A	Closed - In Follow Up	Y
11/LO/1381	A phase II double-blind placebo-controlled randomized study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhibitortherapy	5	31/01/2013	Closed - In Follow Up	Y
13/LO/0033	Genentech GO28509-PEGGY: A PHASE II, randomized STUDY OF paclitaxel with GDC-0941 versus paclitaxel with placebo IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC BREAST CANCER	3	01/09/2014	Closed - In Follow Up	Y

10/H0703/69	A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ONARTUZUMAB AND/OR BEVACIZUMAB IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH METASTATIC, TRIPLE-NEGATIVE BREAST CANCER	5	31/03/2013	Closed - Follow Up Complete	Y
11/WM/0048	A PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF FOUR 12-WEEK TREATMENT CYCLES (48 WEEKS TOTAL) OF EPRATUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS SUBJECTS WITH MODERATE TO SEVERE DISEASE (EMBODY 1)	3	01/06/2014	Closed - Follow Up Complete	Y
11/NW/0200	A Phase 2b dose ranging study to evaluate the efficacy and safety of sifalimumab in adult subjects with systemic lupus erythematosus	2	05/10/2012	Closed - Follow Up Complete	Y
12/SC/0469	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy	6	01/09/2014	Closed - Follow Up Complete	N
11/NW/0338	Clinical Outcomes Study to compare effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate COPD and a history of or at increased risk for cardiovascular disease.	8	03/03/2014	Withdrawn	N
12/SW/0378	Effect of Bivalirudin on Aortic Valve Intervention outcomes 2/3	20	01/04/2015	Open	N/A
13/LO/0574	Phase 3 Randomized Double-Blind Study to Evaluate Safety/Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide vs Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1+ Antiretroviral Treatment-Naive Adults	10	23/07/2013	Closed - In Follow Up	N
13/LO/0821	A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment	5	31/12/2013	Closed - In Follow Up	N
13/LO/0830	Phase 3 open label study evaluating efficacy/safety of pegylated interferon lambda-1a, in combination + ribavirin and daclatasvir, for treatment of chronic HCV infection + treatment na?ve genotypes 1, 2, 3 or 4 in subjects co-infected + HIV	5	31/10/2014	Closed - Follow Up Complete	N
13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL? Haemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery	10	28/02/2014	Open	Y
13/NW/0316	Phase 4 trial comparing cumulative incidence of SCC after treatment + ingenol mebutate & imiquimod for multiple actinic keratoses on face & scalp. A multi-centre, randomised, two-arm, open label, active-controlled, parallel group, 36-month trial.	8	31/05/2015	Open	Y

13/SC/0279	A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV1 Positive Subjects.	Rollover from GS 0106/0114 /0103 no target	17/01/2014	Closed - In Follow Up	N/A
10/H0715/57	Phase 3 efficacy and safety study of oral MDV3100 in chemo na?ve patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy	10	01/09/2012	Closed - In Follow Up	N
11/NW/0597	An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Reg	2	30/06/2015	Closed - In Follow Up	N
13/NW/0501	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to compare efficacy and safety of Oral Azacitidine plus best supportive care versus best supportive care as Maintenance Therapy in subjects with Acute Myelogenous Leukemia in complete remission	3	15/02/2018	Open	Y
13/SC/0480	A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated Systolic Hypertension insufficiently treated with 1-3 anti	10	28/02/2014	Closed - Follow Up Complete	N
13/LO/0671	A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301.	3	05/02/2014	Closed - In Follow Up	Y
13/NW/0560	Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo	8	20/06/2014	Open	N
13/LO/0908	A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer	2	30/12/2015	Closed - In Follow Up	Y
13/LO/1795	A double-blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of subcutaneous administration of human plasma-derived C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema	2	30/06/2015	Closed - In Follow Up	N
14/LO/0440	Prospective Randomised Controlled Trial comparing Monofocal Intraocular Lenses and Limbal Relaxing Incisions with Toric Intraocular Lenses for correcting Astigmatism up to 2.5 Diopters during standard cataract surgery.	80	31/05/2015	Open	N/A

13/LO/1720	A Phase 2, Randomized, Double Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive and HER2 Normal	6	15/04/2016	Open	N/A
14/SC/0225	Gilead 311-1089 Phase 3 randomised open-label switch study to evaluate F/TAF in HIV-1 positive subjects who are virologically suppressed on regimens containing FTC/TAF	8	31/05/2016	Closed - in follow up	N
13/YH/0282	ACT-MOVE: ML28641 - Subcutaneous tocilizumab in rheumatoid arthritis	3	30/06/2014. 1/1/15??	Open	N/A
13/EE/0126	Evaluation of Safety and Efficacy of the BACE™ [Basal Annuloplasty of the Cardia Externally] Device in the Treatment of Functional Mitral Valve Regurgitation [FMR]	6	01/07/2016	Open	N/A
14/LO/0081	A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus	3	31/05/2015	Open	N/A
14/NW/0017	A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients.	6	30/11/2015	Closed - in follow up	Y
12/SS/0138	REstart or STop Antithrombotics Randomised Trial (RESTART).	12	01/06/2015	Open	N/A
13/LO/1081	PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer	4	01/02/2016	Open	N/A
11/AL/0081	SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castraterefractory prostate cancer: a phase I/randomised phase II study by the UK NCRI Prostate Clinical Studies Group	5	30/04/2015	Open	N/A
13/NE/0126	An exploratory, randomised, double-blind, controlled study to assess the effect of an Amino Acid Based Formula with a synbiotic blend on gut microbiota and stool characteristics in infants with suspected gastrointestinal Non IgE mediated cow's milk allergy (CMA).	8	28/07/2014	Open	N
14/SW/0079	A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic DEFLECTION Device during Transcatheter Aortic Valve Implantation	6	01/12/2014	Open	N/A
13/LO/0451	The United Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) Trial. A multi-centre randomised controlled trial to assess the clinical effectiveness and cost-utility of TAVI, compared with conventional surgical aortic valve replacement, in patients with severe symptomatic aortic stenosis at intermediate or high operative risk.	20	31/01/2018	Open	N/A

14/EM/0129	A PHASE 2/3, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED (PART A) AND DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED (PART B), PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RPC1063 ADMINISTERED ORALLY TO RELAPSING MULTIPLE SCLEROSIS PATIENTS	6	01/05/2015	Open	N/A
14/WS/0004	Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732, & LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia	2	31/10/2014	Closed - In Follow Up	Y
14/LO/0121	A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer	3	N/A	Open	N/A
14/LO/1381	Reformulated raltegravir q.d. (1200 mg) versus raltegravir b.i.d. (400 mg) in ART-naïve pts	5	30/04/2015	Open	Y
14/LO/1513	A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir plus Emtricitabine/Tenofovir DF or Efavirenz /Emtricitabine/Tenofovir DF) compared to Ritonavir boosted Atazanavir plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults with eGFR ≥70 mL/min	3	31/12/2015	Open	N/A
14/LO/0298	A multicenter, Single Arm Study of Enzalutamide in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate.	10	01/08/2016	Open	N/A
14/LO/1052	A Phase 2, Randomized, OpenLabel,Parallel Group Study Evaluating the Safety and Efficacy of TAK385, an Oral Gonadotropin Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)	2	N/A	Open	N/A
14/YH/0088	Phase I study of KHK2823 in Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome	4	01/12/2017	Withdrawn	N/A
14/YH/0086	RESPOND: Repositionable Lotus Valve System-Post Market Evaluation of Real World Clinical Outcomes	15	31/12/2015	Open	N/A
14/SC/1161	Prospective, single-arm, Multi-centre, observational registry to Further Validate Safety and Efficacy of the Ultimaster DES system in unselected patients representing everyday clinical practice	30	01/12/2015	Open	N/A
13/LO/1891	More Response on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP)	15	01/12/2016	Open	N/A
13/EM/0348	Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan® 0.01 % and Lumigan® 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan® 0.01 % with ocular surface intoler	5	31/07/2015	Open	N/A

13/YH/0394	Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) withdrawal in adncace renal disease; The STOP-ACEi Trial	10	01/06/2016	Open	N/A
13/YH/0147	A Randomized, Open Label, Multi-Centre, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects with Acute Alcoholic Hepatitis (AAH) Who Have Failed Steroid Therapy (incorporating VTI-210E as a follow-up registry)	6	31/08/2015	Open	N/A
14/WM/0013	A Randomized, Double blind, Placebo-Controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized with Respiratory Syncytial Virus (RSV) Infection.	4	30/04/2015	Open	N/A
14/EM/1070	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	1	01/10/2015	Open	N/A